1. Academic Validation
  2. Terminal Cyclohexane-Type Meroterpenoids from the Fruiting Bodies of Ganoderma cochlear

Terminal Cyclohexane-Type Meroterpenoids from the Fruiting Bodies of Ganoderma cochlear

  • Front Chem. 2021 Dec 3:9:783705. doi: 10.3389/fchem.2021.783705.
Fu-Ying Qin 1 Te Xu 1 Yan-Peng Li 1 Hao-Xing Zhang 1 Dan Cai 1 Li-Zhong Liu 1 Yong-Xian Cheng 1 2
Affiliations

Affiliations

  • 1 School of Pharmaceutical Sciences, School of Medicine, College of Life Sciences and Oceanography, Health Science Center, Institute for Inheritance-Based Innovation of Chinese Medicine, Shenzhen University, Shenzhen, China.
  • 2 Guangdong Key Laboratory for Functional Substances in Medicinal Edible Resources and Healthcare Products, School of Life Sciences and Food Engineering, Hanshan Normal University, Chaozhou, China.
Abstract

Eleven new cyclohexane-type meroterpenoids (1, 3-5, 7, 8, 11-15) and four known similar meroterpenoids (2, 6, 9, and 10) were isolated from Ganoderma cochlear. Their structures and absolute configurations at stereogenic centers were elucidated by using HRESIMS, NMR spectroscopy and computational methods. In addition, the structure of the known meroterpenoid, cochlearol G (2), was revised, and the absolute configurations at the stereogenic centers of known meroterpenoids 9 and 10 were determined. All the isolated meroterpenoids were evaluated for their activities against renal fibrosis and triple negative breast Cancer, and their Insulin resistance. The results of the renal fibrosis study showed that meroterpenoid 11 inhibits over-expression of fibronectin, Collagen I and α-SMA. Results of the wound healing study revealed that 4, 6 and 8 significantly inhibit migration of BT549 cells. Observations made in Western blotting experiments showed that 6 decreases the levels of TWIST1 and ZEB1, and increases the level of E-cadherin. Finally, meroterpenoids 7, 9, 11, and 15 significantly up-regulate p-AMPK protein expression in normal L6 myotubes cells.

Keywords

BT549 cells; Ganoderma cochlear; meroterpenoids; renal fibrosis; triple negative breast cancer.

Figures
Products
Inhibitors & Agonists